Hypolipemic pancreatic, gastric and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A2
, liver esterase, trypsin and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G1
/S boundary in vitro
. Prevents the absorption of approximately one third of fat from food and exhibits progastrokinetic, antiobesity and antihypercholesterolemic activity in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase.
Hadvary et al.
Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity.
Kridel et al.
Cancer Res., 2004;64:2070
Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects.
Enc et al.
Am.J.Physiol.Gastrointest.Liver Physiol., 2008;296:G482
The citations listed below are publications that use Tocris products. Selected citations for Orlistat include:
Showing Results 1 - 2 of 2